The board of directors of biopharmaceutical company Pfizer Inc (NYSE:PFE) approved a dividend payment of USD0.38 per share on the company's common stock for the first-quarter 2020, it declared on Monday.
Pfizer stated that the 6% higher quarterly payment reflects its 325th consecutive quarterly dividend.
This dividend will be paid on 6 March 2020 to holders of the common stock of record at the close of business as of 31 January 2020.
Also, the company said it plans to host an Investor Day at 9:00 a.m. EDT on 31 March 2020, at its global headquarters in New York, NY, to provide updates on its progress in advancing its R&D pipeline, product candidates with blockbuster potential that are expected to launch by 2025.
Pfizer collaborates with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world.
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government
Fusion Antibodies secures multi-target humanisation contract with global pharmaceutical client
Genmab to acquire Merus in USD8bn deal to strengthen oncology pipeline
Wolters Kluwer launches UpToDate Expert AI to deliver trusted GenAI clinical decision support
CVS Health declares unchanged quarterly dividend
ALK partners with GenSci to expand allergy immunotherapy market in China
Curatis secures Swiss distribution deal with Phoenix Labs
Innocan Pharma reports 'positive swing' in operating profitability for first half of 2025
Wolters Kluwer boosts medical research efficiency with Ovid AI summarisation